|
Endometriosis
|
0.310 |
Biomarker
|
disease |
BEFREE |
Among the progestins that are currently used for treatment of endometriosis, dydrogesterone, medroxyprogesterone acetate and 20α-dihydrodydrogesterone act as AKR1C2 inhibitors with low μM K(i) values in vitro.
|
22245609 |
2012 |
|
Malignant neoplasm of prostate
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Additional studies are needed to further define the significance of reduced AKR1C2 expression in prostate cancer and its potential role in modulating local availability of DHT.
|
12539226 |
2003 |
|
Malignant neoplasm of prostate
|
0.060 |
Biomarker
|
disease |
BEFREE |
Modulation of AKR1C2 by curcumin decreases testosterone production in prostate cancer.
|
29369461 |
2018 |
|
Malignant neoplasm of prostate
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
We found significant up regulation of 5α-reductase type 1 and type 3 in both primary and metastatic PC, together with the down regulation of AKR1C2 in primary PC, contributing to the high intratumoral DHT levels.
|
31783154 |
2020 |
|
Malignant neoplasm of prostate
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of AKR1C2 is associated with disease progression in prostatic cancer.
|
20840669 |
2010 |
|
Malignant neoplasm of prostate
|
0.060 |
Biomarker
|
disease |
BEFREE |
To study the significance of AKR1C2- and AKR1C3-mediated PGD2 conversion in human prostate cell proliferation, we stably transfected androgen insensitive human prostate cancer PC-3 cells with AKR1C2 or AKR1C3 cDNA.
|
18508192 |
2008 |
|
Malignant neoplasm of prostate
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
In primary cultures of epithelial cells, high levels of AKR1C2 transcripts were detected in prostate cancer, but not in cells from normal prostate.
|
12810547 |
2003 |
|
Prostate carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
To study the significance of AKR1C2- and AKR1C3-mediated PGD2 conversion in human prostate cell proliferation, we stably transfected androgen insensitive human prostate cancer PC-3 cells with AKR1C2 or AKR1C3 cDNA.
|
18508192 |
2008 |
|
Prostate carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Modulation of AKR1C2 by curcumin decreases testosterone production in prostate cancer.
|
29369461 |
2018 |
|
Prostate carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
In primary cultures of epithelial cells, high levels of AKR1C2 transcripts were detected in prostate cancer, but not in cells from normal prostate.
|
12810547 |
2003 |
|
Prostate carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
We found significant up regulation of 5α-reductase type 1 and type 3 in both primary and metastatic PC, together with the down regulation of AKR1C2 in primary PC, contributing to the high intratumoral DHT levels.
|
31783154 |
2020 |
|
Prostate carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Additional studies are needed to further define the significance of reduced AKR1C2 expression in prostate cancer and its potential role in modulating local availability of DHT.
|
12539226 |
2003 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
STITCH database was used for predicting the plant constituents target proteins/genes, TDD DB and Uniprot databases were used for identifying genes related to cancer.
|
30910579 |
2019 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Both AKR1C1 and AKR1C2 proteins are involved in cancer pro-proliferative cell chemoresistance.
|
20824049 |
2010 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
We subsequently analyzed the data and obtained the following findings: (a) AKR1C2 is down-regulated in papillary thyroid carcinoma (PTC) (<i>p</i><0.001), (b) Kaplan-Meier result revealed that high expression level of AKR1C2 are correlated with favorable survival in PTC (<i>p</i> = 0.043), and (c) factors independently associated with recurrence-free survival are AKR1C2 expression (hazard ratio (HR 0.819) and American Joint Committee on Cancer (AJCC) stage (HR 1.534).
|
31293659 |
2019 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Overexpression of AKR1C1 and, to a lesser extent, AKR1C2 (but not AKR1C3) decreased progesterone-dependent PR activation of a mouse mammary tumor virus promoter in both prostate (PC-3) and breast (T-47D) cancer cell lines.
|
15492289 |
2004 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Both AKR1C1 and AKR1C2 proteins are involved in cancer pro-proliferative cell chemoresistance.
|
20824049 |
2010 |
|
Primary malignant neoplasm
|
0.040 |
AlteredExpression
|
group |
BEFREE |
We subsequently analyzed the data and obtained the following findings: (a) AKR1C2 is down-regulated in papillary thyroid carcinoma (PTC) (<i>p</i><0.001), (b) Kaplan-Meier result revealed that high expression level of AKR1C2 are correlated with favorable survival in PTC (<i>p</i> = 0.043), and (c) factors independently associated with recurrence-free survival are AKR1C2 expression (hazard ratio (HR 0.819) and American Joint Committee on Cancer (AJCC) stage (HR 1.534).
|
31293659 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
STITCH database was used for predicting the plant constituents target proteins/genes, TDD DB and Uniprot databases were used for identifying genes related to cancer.
|
30910579 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Overexpression of AKR1C1 and, to a lesser extent, AKR1C2 (but not AKR1C3) decreased progesterone-dependent PR activation of a mouse mammary tumor virus promoter in both prostate (PC-3) and breast (T-47D) cancer cell lines.
|
15492289 |
2004 |
|
Adult Liver Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of AKR1C1 and AKR1C2 in liver cancer tissues did not increase significantly in the Oncomine database while expression was significantly high in CCLE and GEPIA databases.
|
31611960 |
2019 |
|
Adult Liver Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
We identified two powerful genes in the liver cancer metastasis process, AEG-1 and AKR1C2, both of which proved to be positive regulators in promoting metastasis in liver cancer.
|
26318406 |
2016 |
|
Adult Liver Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Through deep sequencing and expression regulation analysis in liver cancer cells, we identified two novel factors, AKR1C2 (positive factor) and NF1 (negative factor), as the AEG-1 downstream players in the process of metastasis in liver cancer.
|
26351209 |
2014 |
|
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The expression levels of AKR1C1 and AKR1C2 in liver cancer tissues did not increase significantly in the Oncomine database while expression was significantly high in CCLE and GEPIA databases.
|
31611960 |
2019 |
|
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Through deep sequencing and expression regulation analysis in liver cancer cells, we identified two novel factors, AKR1C2 (positive factor) and NF1 (negative factor), as the AEG-1 downstream players in the process of metastasis in liver cancer.
|
26351209 |
2014 |